AHC Ballana Heart Study

Genetic Predisposition to Disease Clinical Trial

— AHC-BHS  

Official title:

Aswan Heart Centre - Ballana Heart Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05661318
• Other study ID #: AHC-BHS
• Status: Recruiting
• Start date: January 1, 2018
• Est. completion date: January 31, 2055

Study information

• Verified date: May 2024
• Source: Magdi Yacoub Heart Foundation
• Contact: Yasmine Aguib, PhD
• Phone: +201092036368
• Email: yasmine.aguib[@]aswanheartcentre.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

This Study is designed to assess CVD incidence, prevalence, progression and related risk factors, including genetic background. It will provide an important base for all cardiovascular research activities in our centre and help in designing future studies and guide policy.

Description:

Background Population-based longitudinal studies are a cornerstone in understanding current disease landscapes affecting communities and collecting reliable data to guide prevention and treatment strategies. In Egypt there is pressing need of collecting reliable data on cardiovascular disease (CVD) in defined populations.

Objectives Defining the cardiovascular phenotype, genotype as well as OMICS and risk factors for CVD in a defined population in Egypt with follow up for up to 30 years

Methods As a first step, a random representative sample of 1,200 households from the Ballana population will be created. Following inclusion, patients will be screened for their cardiovascular profile and followed up for changes in their profile and cardiovascular events continuously every year in high risk patients and every 3 years for the rest of the participants for a period of 30 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 5000
• Est. completion date: January 31, 2055
• Est. primary completion date: December 31, 2050
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Residents of Ballana from the 1,200 randomly selected households

• Participants must have a valid National ID card

• Written informed consent

Exclusion criteria:

• Residents who are younger than 18 years

Related Conditions & MeSH terms

• Genetic Predisposition to Disease

Intervention

Other:
• Risk assessment
Collect clinical, laboratoary and genetics data from the participants after informed consent

Locations

Country	Name	City	State
Egypt	Aswan Heart Centre - Magdi Yacoub Heart Foundation	Aswan

Sponsors (1)

Lead Sponsor	Collaborator
Magdi Yacoub Heart Foundation

Country where clinical trial is conducted

Egypt, 

References & Publications (1)

Keates AK, Mocumbi AO, Ntsekhe M, Sliwa K, Stewart S. Cardiovascular disease in Africa: epidemiological profile and challenges. Nat Rev Cardiol. 2017 May;14(5):273-293. doi: 10.1038/nrcardio.2017.19. Epub 2017 Feb 23. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cardiovascular risk assessment		30 years